Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Nicholas J Mercuro, Susan L Davis, Marcus J Zervos & Erica S Herc. (2018) Combatting resistant enterococcal infections: a pharmacotherapy review. Expert Opinion on Pharmacotherapy 19:9, pages 979-992.
Read now
Read now
Jason W Bennett, James S Lewis$suffix/text()$suffix/text() & Michael W Ellis. (2008) Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Therapeutics and Clinical Risk Management 4:1, pages 31-40.
Read now
Read now
Kristina E Ward, Tracey L Mersfelder & Kerry L LaPlante. (2006) Oritavancin – an investigational glycopeptide antibiotic. Expert Opinion on Investigational Drugs 15:4, pages 417-429.
Read now
Read now
R.N. Jones, T.R. Fritsche, H.S. Sader & B.P. Goldstein. (2005) Antimicrobial Spectrum and Potency of Dalbavancin Tested Against Clinical Isolates from Europe and North America (2003): Initial Results from an International Surveillance Protocol. Journal of Chemotherapy 17:6, pages 593-600.
Read now
Read now
André Bryskier. (2005) Anti-MRSA agents: under investigation, in the exploratory phase and clinically available. Expert Review of Anti-infective Therapy 3:4, pages 505-553.
Read now
Read now
Neil Woodford. (2003) Novel agents for the treatment of resistant Gram-positive infections. Expert Opinion on Investigational Drugs 12:2, pages 117-137.
Read now
Read now
Articles from other publishers (40)
Aaron K. Hoyt, Patrick Lawler, Mathias Bostrom, Alberto V. Carli & Ashley E. Levack. (2023)
Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive
Staphylococcus Aureus
. Journal of Bone and Joint Infection 8:3, pages 175-181.
Crossref
Crossref
Paul Ettel, Al Nasar Ahmed Sehgal, Nicole Harrison, Winfried F. Pickl & Katharina Grabmeier-Pfistershammer. (2023) Glycopeptide Antibiotics Impair Neutrophil Effector Functions. International Archives of Allergy and Immunology, pages 1-17.
Crossref
Crossref
Kyle C. Molina, Matthew A. Miller, Scott W. Mueller, Edward T. Van Matre, Martin Krsak & Tyree H. Kiser. (2021) Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clinical Pharmacokinetics 61:3, pages 363-374.
Crossref
Crossref
Katharina Neudorfer, Suzannah M. Schmidt-Malan & Robin Patel. (2018) Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci. Diagnostic Microbiology and Infectious Disease 90:1, pages 58-63.
Crossref
Crossref
Biswadeep Das, Chayna Sarkar, Debasmita Das, Amit Gupta, Arnav Kalra & Shubham Sahni. (2017) Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Therapeutic Advances in Infectious Disease 4:2, pages 49-73.
Crossref
Crossref
Stefano Biondi, Elena Chugunova & Mauro Panunzio. 2016.
249
297
.
Michael PfallerAryun Kim, Joseph Kuti & David Nicolau. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
645
653
.
Kristin H. BusseKate M. OltroggeCarolyn J. OxencisWilliam J. Peppard. (2017) Dalbavancin: A Review of Its Use in the Treatment of Gram-positive Infections. Clinical Medicine Insights: Therapeutics 2, pages CMT.S1953.
Crossref
Crossref
Neil. Woodford. 2010. Antibiotic and Chemotherapy. Antibiotic and Chemotherapy
265
271
.
Patricia Poeta, Hajer Radhouani, Roberto Sargo & Gilberto Igrejas. (2008)
In vitro
activity of dalbavancin against enterococci isolates from wild animals, pets, poultry and humans in Portugal
. Journal of Basic Microbiology 48:6, pages 526-528.
Crossref
Crossref
L. D. Saravolatz, M. Billeter, M. J. Zervos, A. Y. Chen, J. R. Dalovisio & C. Kurukularatne. (2008) Dalbavancin: a Novel Once-Weekly Lipoglycopeptide Antibiotic. Clinical Infectious Diseases 46:4, pages 577-583.
Crossref
Crossref
Ryan J. Attwood & Kerry L. LaPlante. (2007) Telavancin: A novel lipoglycopeptide antimicrobial agent. American Journal of Health-System Pharmacy 64:22, pages 2335-2348.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
Ellie J. C. Goldstein, Diane M. Citron, Yumi A. Warren, Kerin L. Tyrrell, C. Vreni Merriam & Helen T. Fernandez. (2006) In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections. Antimicrobial Agents and Chemotherapy 50:8, pages 2875-2879.
Crossref
Crossref
Andrej Trampuz & Andreas F Widmer. (2006) Infections associated with orthopedic implants. Current Opinion in Infectious Diseases 19:4, pages 349-356.
Crossref
Crossref
Ronald N. Jones, Helio S. Sader, Thomas R. Fritsche, Patricia A. Hogan & Daniel J. Sheehan. (2006) Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program. Journal of Clinical Microbiology 44:7, pages 2622-2625.
Crossref
Crossref
Shu-Wen Lin, Peggy L Carver & Daryl D DePestel. (2016) Dalbavancin: A New Option for the Treatment of Gram-Positive Infections. Annals of Pharmacotherapy 40:3, pages 449-460.
Crossref
Crossref
Beth P. Goldstein, Ronald N. Jones, Thomas R. Fritsche & Douglas J. Biedenbach. (2006) Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagnostic Microbiology and Infectious Disease 54:2, pages 83-87.
Crossref
Crossref
Ronald N. Jones, Matthew G. Stilwell, Helio S. Sader, Thomas R. Fritsche & Beth P. Goldstein. (2006) Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagnostic Microbiology and Infectious Disease 54:2, pages 149-153.
Crossref
Crossref
Andrej Trampuz & Werner Zimmerli. (2006) Antimicrobial Agents in Orthopaedic Surgery. Drugs 66:8, pages 1089-1105.
Crossref
Crossref
Alexander von Graevenitz & Kathryn Bernard. 2006. The Prokaryotes. The Prokaryotes
819
842
.
Gengrong Lin, Kathy Smith, Lois M. Ednie & Peter C. Appelbaum. (2005) Antipneumococcal Activity of Dalbavancin Compared to Other Agents. Antimicrobial Agents and Chemotherapy 49:12, pages 5182-5184.
Crossref
Crossref
Jennifer M. Streit, Helio S. Sader, Thomas R. Fritsche & Ronald N. Jones. (2005) Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagnostic Microbiology and Infectious Disease 53:4, pages 307-310.
Crossref
Crossref
John A. Bosso. (2005) The Antimicrobial Armamentarium: Evaluating Current and Future Treatment Options. Pharmacotherapy 25:10 Part 2, pages 55S-62S.
Crossref
Crossref
André Bryskier. 2005. Antimicrobial Agents. Antimicrobial Agents
1183
1238
.
A. Bryskier & P. Veyssier. 2005. Antimicrobial Agents. Antimicrobial Agents
880
905
.
Gengrong Lin, Kim Credito, Lois M. Ednie & Peter C. Appelbaum. (2005) Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide. Antimicrobial Agents and Chemotherapy 49:2, pages 770-772.
Crossref
Crossref
A.C. Gales, H.S. Sader & R.N. Jones. (2005) Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clinical Microbiology and Infection 11:2, pages 95-100.
Crossref
Crossref
N. Woodford. (2005) Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clinical Microbiology and Infection 11, pages 2-21.
Crossref
Crossref
Daniela Jabés, Gianpaolo Candiani, Gabriella Romanó, Cristina Brunati, Simona Riva & Marco Cavaleri. (2004)
Efficacy of Dalbavancin against Methicillin-Resistant
Staphylococcus aureus
in the Rat Granuloma Pouch Infection Model
. Antimicrobial Agents and Chemotherapy 48:4, pages 1118-1123.
Crossref
Crossref
Anton Leighton, Alice Bendix Gottlieb, Mary Beth Dorr, Daniela Jabes, Giorgio Mosconi, Claudia VanSaders, Edward J. Mroszczak, Kathleen C. M. Campbell & Ellen Kelly. (2004) Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 48:3, pages 940-945.
Crossref
Crossref
Agnès Lefort, Juliette Pavie, Louis Garry, Françoise Chau & Bruno Fantin. (2004)
Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to
Staphylococcus aureus
with or without Reduced Susceptibility to Vancomycin and Teicoplanin
. Antimicrobial Agents and Chemotherapy 48:3, pages 1061-1064.
Crossref
Crossref
Ronald N Jones, Jennifer M Streit & Thomas R Fritsche. (2004) Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. International Journal of Antimicrobial Agents 23:2, pages 197-199.
Crossref
Crossref
Jennifer M Streit, Thomas R Fritsche, Helio S Sader & Ronald N Jones. (2004) Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagnostic Microbiology and Infectious Disease 48:2, pages 137-143.
Crossref
Crossref
Murugan Raghavan & Peter K Linden. (2004) Newer Treatment Options for Skin and Soft Tissue Infections. Drugs 64:15, pages 1621-1642.
Crossref
Crossref
Fran??oise Van Bambeke, Yves Van Laethem, Patrice Courvalin & Paul M Tulkens. (2004) Glycopeptide Antibiotics. Drugs 64:9, pages 913-936.
Crossref
Crossref
E. Seltzer, M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell & T. Henkel. (2003) Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections. Clinical Infectious Diseases 37:10, pages 1298-1303.
Crossref
Crossref
Tamara R. Anderegg, Douglas J. Biedenbach & Ronald N. Jones. (2003) Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity. Journal of Clinical Microbiology 41:6, pages 2795-2796.
Crossref
Crossref
Ellie J. C. Goldstein, Diane M. Citron, C. Vreni Merriam, Yumi Warren, Kerin Tyrrell & Helen T. Fernandez. (2003) In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria. Antimicrobial Agents and Chemotherapy 47:6, pages 1968-1971.
Crossref
Crossref